<SEC-DOCUMENT>0001047469-19-001206-index.html : 20190314 <SEC-HEADER>0001047469-19-001206.hdr.sgml : 20190314 <ACCEPTANCE-DATETIME>20190314060259 ACCESSION NUMBER: 0001047469-19-001206 CONFORMED SUBMISSION TYPE: S-3/A PUBLIC DOCUMENT COUNT: 6 FILED AS OF DATE: 20190314 DATE AS OF CHANGE: 20190314 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Vaxart, Inc. CENTRAL INDEX KEY: 0000072444 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 591212264 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: S-3/A SEC ACT: 1933 Act SEC FILE NUMBER: 333-228910 FILM NUMBER: 19679658 BUSINESS ADDRESS: STREET 1: 290 UTAH AVE., SUITE 200 CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 BUSINESS PHONE: (650) 550-3500 MAIL ADDRESS: STREET 1: 290 UTAH AVE., SUITE 200 CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 FORMER COMPANY: FORMER CONFORMED NAME: Aviragen Therapeutics, Inc. DATE OF NAME CHANGE: 20160413 FORMER COMPANY: FORMER CONFORMED NAME: Biota Pharmaceuticals, Inc. DATE OF NAME CHANGE: 20121113 FORMER COMPANY: FORMER CONFORMED NAME: NABI BIOPHARMACEUTICALS DATE OF NAME CHANGE: 20100719 </SEC-HEADER> <DOCUMENT> <TYPE>S-3/A <SEQUENCE>1 <FILENAME>a2238055zs-3a.htm <DESCRIPTION>S-3/A <TEXT> Document 1 - file: a2238055zs-3a.htm
</DOCUMENT> <DOCUMENT> <TYPE>EX-5.1 <SEQUENCE>2 <FILENAME>a2238055zex-5_1.htm <DESCRIPTION>EX-5.1 <TEXT> Document 2 - file: a2238055zex-5_1.htm
</DOCUMENT> <DOCUMENT> <TYPE>EX-23.1 <SEQUENCE>3 <FILENAME>a2238055zex-23_1.htm <DESCRIPTION>EX-23.1 <TEXT> Document 3 - file: a2238055zex-23_1.htm
</DOCUMENT> <DOCUMENT> <TYPE>GRAPHIC <SEQUENCE>4 <FILENAME>g227642.jpg <DESCRIPTION>G227642.JPG <TEXT> Document 4 - file: g227642.jpg
</DOCUMENT> <DOCUMENT> <TYPE>GRAPHIC <SEQUENCE>5 <FILENAME>g396757.jpg <DESCRIPTION>G396757.JPG <TEXT> Document 5 - file: g396757.jpg
</DOCUMENT> <DOCUMENT> <TYPE>GRAPHIC <SEQUENCE>6 <FILENAME>g421744.jpg <DESCRIPTION>G421744.JPG <TEXT> Document 6 - file: g421744.jpg
</DOCUMENT> </SEC-DOCUMENT>